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Background: Dosimetry for toxicology studies involving carbon nanotubes (CNT) is challenging because of a lack
of detailed occupational exposure assessments. Therefore, exposure assessment findings, measuring the mass
concentration of elemental carbon from personal breathing zone (PBZ) samples, from 8 U.S.-based multi-walled
CNT (MWCNT) manufacturers and users were extrapolated to results of an inhalation study in mice.
Results: Upon analysis, an inhalable elemental carbon mass concentration arithmetic mean of 10.6 μg/m3
(geometric mean 4.21 μg/m3) was found among workers exposed to MWCNT. The concentration equates to a
deposited dose of approximately 4.07 μg/d in a human, equivalent to 2 ng/d in the mouse. For MWCNT inhalation,
mice were exposed for 19 d with daily depositions of 1970 ng (equivalent to 1000 d of a human exposure;
cumulative 76 yr), 197 ng (100 d; 7.6 yr), and 19.7 ng (10 d; 0.76 yr) and harvested at 0, 3, 28, and 84 d
post-exposure to assess pulmonary toxicity. The high dose showed cytotoxicity and inflammation that persisted
through 84 d after exposure. The middle dose had no polymorphonuclear cell influx with transient cytotoxicity. The
low dose was associated with a low grade inflammatory response measured by changes in mRNA expression. Increased
inflammatory proteins were present in the lavage fluid at the high and middle dose through 28 d post-exposure.
Pathology, including epithelial hyperplasia and peribronchiolar inflammation, was only noted at the high dose.
Conclusion: These findings showed a limited pulmonary inflammatory potential of MWCNT at levels corresponding to
the average inhalable elemental carbon concentrations observed in U.S.-based CNT facilities and estimates suggest
considerable years of exposure are necessary for significant pathology to occur at that level.
Keywords: Workplace exposure assessment, Inhalation exposure, Mouse model, MWCNT Dose response and time
dependence, Protein, Gene expressionIntroduction
The pulmonary toxicity of carbon nanotubes (CNT) has
been well described. Findings from CNT inhalation ex-
posures included cytotoxicity, inflammatory cell influx,
and interstitial fibrosis in the lung [1-6]. Some more re-
cent studies also suggest the potential of CNT to promote
lung tumorigenesis [7]. Several studies also have shown
systemic effects such as immunosuppression, systemic* Correspondence: efi4@cdc.gov
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reproduction in any medium, provided the orinflammation, and changes in molecular signaling in
extrapulmonary tissues [8-12]. Reduced vascular respon-
siveness and increased suceptibility to ischemia / reperfu-
sion injury in cardiac tissue were also a product of CNT
exposure [13,14].
In the above studies there is a lack of a correlation to
occupational exposures in workers primarily due to the
paucity of human exposure assessment data. This may re-
flect the fact that workforce sizes for CNT remain small
[15]. There is little consensus on exposure assessment
methods and exposure metrics (particle number, surface
area, and mass) that best correlate with adverse health
outcomes, although particle number is often dominatedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Erdely et al. Particle and Fibre Toxicology 2013, 10:53 Page 2 of 14
http://www.particleandfibretoxicology.com/content/10/1/53by ultrafine or non-engineered nanoparticle sources
[16,17]. Traditionally, exposure assessment methods for
workplace exposures to particulates have focused on the
collection of gravimetric samples which has complica-
tions for particles in the ultrafine size range, though
CNT occur mainly as micrometer-sized aggregates [18].
Similarly, early exposure assessment studies for CNT,
which reported personal breathing zone (PBZ) samples
collected within workplaces, focused on the collection
of samples for the total gravimetric mass of all particles
or indirectly estimated mass specific to CNT [19-21].
PBZ mass concentration ranges for these studies are
summarized in Table 1 by type of exposure data collected.
Maynard et al. collected the total mass of a metal
catalyst used to produce single-walled (SW) CNT and
then estimated the mass of SWCNT exposures to be
between 0.7 - 53 μg/m3 [21]. Another study conducted
by Han et al. collected full-shift samples for the total
mass of all particulates in a multi-walled (MW) CNT
research facility and found PBZ concentrations ranging
from non-detectable concentrations - 331.7 μg/m3 [19].
The exposures at the high end were measured during
blending of CNT with no control measures. Once control
measures were in place, exposure was greatly diminished.
Similarly, Lee et al. visited seven facilities ranging from in-
dustrial settings to lab scale settings and found full-shift
total gravimetric mass concentrations from PBZ measure-
ments to range from 7.8 - 320.8 μg/m3 [20].
The interpretation of gravimetric sampling for high
aspect ratio carbon-based nanomaterials, including
CNT and carbon nanofibers (CNF), has proven difficult
due to the unique characteristics of the material which
includes low bulk densities and entangled / bundled
structures rather than discrete fibers. Recently, several
studies have utilized methodologies to measure the
chemical specific mass of elemental carbon, using
NMAM 5040, as a marker for CNT or CNF exposure
(Table 1) [22-24]. The use of this marker has provided a
more refined mass-based workplace exposure estimate,
as opposed to total carbon or gravimetric dust measure-
ments. The study by Methner et al. collected PBZTable 1 Studies with detectable personal breathing zone mas




Total carbon-inhalable size fraction
Elemental carbon- inhalable size fraction
Elemental carbon- inhalable size fraction
Elemental carbon- respirable size fraction
N.D. Represents non-detectable samples.samples at a CNF end user worksite, among many other
nanomaterial facilities, and measured the inhalable
mass of total carbon (elemental + organic carbon), a less
specific marker for CNT exposure [25]. These samples
were collected during short duration exposures, aimed
to identify worst-case scenarios, and found concentra-
tions between 64 μg/m3 - 1094 μg/m3.
Subsequent studies have reported elemental carbon
(EC) measurements, a more specific marker for CNT/
CNF exposure. A more recent study by Methner et al.
found few detectable exposures during short duration
tasks at four SWCNT or CNF downstream user facilities
[24]. PBZ samples were collected and analyzed for EC.
One facility yielded detectable quantities of EC, which
were 33 μg/m3 and 38 μg/m3. Although few of the PBZ
samples had measurable EC concentrations, most of the
collected samples showed evidence of SWCNT or CNF
exposure by electron microscopy [24]. A study conducted
by Birch et al. collected full-shift PBZ samples at a large
volume CNF production facility and found concentrations
at the respirable size fraction of 45 μg/m3 and 80 μg/m3
[22]. Dahm et al. found patterns of exposures between
primary producers and downstreams users of MWCNT,
SWCNT, and CNF materials with EC exposures ranging
from non-detectable concentrations to 7.86 μg/m3 for the
inhalalable size fraction [23]. Overall, the measurement of
EC is a more specific and sensitive marker of exposure
which provides a more realistic workplace exposure con-
centration when compared to gravimetric sampling.
The occupational workforce handling CNT and CNF
(beyond research and development scale) currently
employs at least 500 workers at 61 companies in the U.
S. with an expected growth of about 22% annually
[15,26]. Currently there are no known end-point effects
in humans following CNT exposure. This leads to
extrapolation from rodent studies. Given the toxicity
observed in rodents, epidemiologic studies have been
initiated world-wide [26]. One key question becomes
obvious: how do realistic U.S. workplace exposures
relate to the toxicity found in animal studies? The
present study was designed to address this question.s concentrations
one mass concentrations (μg/m3) Study
0.7 - 53 Maynard et al. 2004 [21]
N.D. - 331.7 Han et al. 2008 [19]
7.8 - 320.8 Lee et al. 2010 [20]
64-1094 Methner et al. 2010 [25]
N.D. - 38 Methner et al. 2012 [24]
N.D. - 7.86 Dahm et al. 2012 [23]
45 - 80 Birch et al. 2011 [22]
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would cause significant inflammation with histological
findings and then a low dose to serve as a no observable
effect level. This design will serve as a reference for de-
tailed molecular analysis, pulmonary pathology, systemic
inflammation, and evaluation of cardiovascular dysfunc-
tion at human relevant exposures.
The inhalation study utilized the MWCNT produced
by Hodogaya, commonly referred to as the Mitsui
MWCNT or MWNT-7. This particular product was
utilized for several reasons: 1.) A majority of the U.S.
workforce handling carbonaceous nanomaterials primarily
produces or utilizes MWCNT [15]. 2.) Economically, the
global market showed that CNT represents 28% of the total
engineered nanomaterial market share with MWCNT
being 94% of the total CNT production value (http://
www.nanowerk.com/spotlight/spotid=23118.php). 3.) The
Hodogaya MWCNT has been extensively characterized
and pulmonary effects are known for certain lung
burdens [5,27]. 4.) Ongoing studies are obtaining and
evaluating specific CNT materials that are being used
primarily in U.S. facilities. Results for the Hodogaya-
produced MWCNT will permit comparison with products
utilized by U.S. facilities.
Results and discussion
Exposure assessment
PBZ elemental carbon measurements in MWCNT facilities
The range of inhalable EC concentrations from PBZ
samples at 8 facilites handling MWCNT are shown in
Figure 1. The figure shows the arithmetic mean exposureFigure 1 Inhalable elemental carbon (EC) concentrations at
eight MWCNT facilities. The mean, with error bars representing the
upper and lower range, of measured EC concentration (μg/m3) with
background correction. The figure was adapted from data previously
published, sites A, C-F [23], while including 3 additional sites, L, J,
and O. The studied sites were identified in a manner to be
consistent with nomenclature of specific sites. For example, site B
was a single-walled carbon nanotube facility and therefore excluded.concentrations with background EC correction for each
site with the error bars indicating the upper and lower
range of measured exposures. The first 5 sites (A,C,D,E,
and F; Site B was excluded due to the production of
SWCNT), were adapted from Dahm et al. [23]. As part of
an ongoing study, an additional 3 MWCNT facilities have
been assessed. These companies produce, utilize, and han-
dle the material throughout the workday as well and have
been added to the existing data.
The average EC concentrations at the inhalable size
fraction from the eight total MWCNT sites was found to
have an arithmetic mean of 10.6 μg/m3 with a standard
deviation of 17.2 (geometric mean- 4.21 μg/m3 and geo-
metric standard deviation of 4.15). In these 8 MWCNT
facilities, exposures ranged from non-detectable samples
to 79.6 μg/m3 and the exposure levels were log normally
distributed (Shapiro-Wilk p=0.97). Nearly all of the sam-
ples that were found to be > 10 μg/m3 came from a single
facility; however, the number of PBZ samples collected at
this site was representative of the facility’s percentage of
the total MWCNT-exposed workforce. Thus, the reported
distribution of exposure levels should reflect the target
population of workers.
The NIOSH Current Intelligence Bulletin on CNT
and CNF has recently published a recommended expos-
ure limit (REL) of 1 μg/m3 for an 8 h time-weighted
average of EC [28]. The REL is for the respirable frac-
tion of CNT. The data discussed in the above results is
for the inhalable fraction. A recently study on the dusti-
ness of various types of nanomaterials provided the res-
pirable to total or inhalable size fraction ratio [29]. Only
one MWCNT and one CNF were reported. Ratios of
0.17 and 0.28 respirable to total were found, respect-
ively. It is anticipated that different types of CNT pow-
ders may behave differently and the ratio of respirable
to inhalable or total may vary depending on the material
handled, the dust generation process, the aerosol con-
centration, and the sampling location. Continuing stud-
ies within nanomaterial facilities are routinely collecting
PBZ respirable fractions for MWCNTs. Preliminary re-
sults indicate similar findings to those predicted by
dustiness studies. Therefore, assuming a 25% respirable
fraction, the respirable fraction as an average of all 8
facilites would be approximately 2.65 μg/m3. This is in
sharp contrast to 45 and 80 μg/m3 of respirable EC
found at a CNF facility [22]. However, this facility
produced large quantities of material and was using
inadequate exposure control strategies. Given that 75%
of MWCNT exposure measurements for inhalable EC
were < 10 μg/m3, it would suggest that exposures to
CNT can be contained with proper engineering controls
[19,23]. However, it should be noted that the possible
health effects of exposure to inhalable (but non-respirable)
MWCNTare unknown.
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In addition to the measure of EC concentrations, rep-
resentative electron microscopy images of samples
collected from MWCNT workplaces were evaluated.
Figure 2 shows the variety of particle types that can be
found in facilities handling MWCNT. In rare instances,
the MWCNT aerosol can be partially comprised of
particles resembling single fibers or bundles of only a
few fibers, Figure 2A. However, it is much more com-
mon to find an aerosol comprised of tangled, agglomer-
ated material several μm in diameter, Figure 2B-D.
Similar findings of both dispersed and tangled CNT and
CNF materials can be found from electron microscopy
results from other studies [19,20,23-25]. These differ-
ences can be related to the physical and chemical char-
acteristics of the type of high aspect ratio carbon-based
nanomaterials being produced as well as the particular
handling process in the facility. These images illustrate
the complexity when designing an in vivo study to
mimic the workplace. Data suggest the degree of disper-
sion is related to the fibrotic potential of CNT [30]. In
addition, a more aggregated SWCNT produced less
pulmonary and systemic inflammation compared to a
more dispersed MWCNT at an equal mass dose [8].
Therefore, given the vast diversity of characteristics of
CNT products, coupled with varying handling pro-
cesses, animal exposures to agglomerated and dispersed
CNT have relevancy to the occupational setting.Figure 2 Images of multi-walled carbon nanotubes collected from fac
zone sampling showed exposures can range from dispersed panel (A) to mExtrapolation of lifetime cumulative worker exposures to
rodent dosimetry
Although the worker exposure data were well de-
scribed by a lognormal distribution, the arithmetic
mean (rather than the geometric mean) was used to
estimate the average cumulative working lifetime
exposure in humans, because the arithmetic mean
(unlike the geometric mean) sums to the appropriate
cumulative total over a time period and/or population
[31]. For this reason, the arithmetic mean is often
preferred over the geometric mean in epidemiologic
studies (e.g. [31,32]). The extrapolation to murine
equivalence was based on standard worker ventilatory
parameters (31% sitting, 69% light exercise with a
minute ventilation of 20 L/min [33]) of a worker
being exposed to 10.6 μg/m3, the average inhalable
EC concentration of MWCNT measured at 8 U. S. fa-
cilities. The alveolar deposition expected in a worker
exposure was estimated. The alveolar deposition will
be dependent on the mass median aerodynamic diam-
eter (MMAD). Dustiness studies showed 0.17 and
0.28 of the inhalable fraction of MWCNT and CNF
to be respirable [29]. Using the ACGIH sampling
criteria for inhalable and respirable fractions, a 25%
respirable fraction would approximate to a MMAD of
roughly 5.5 μm. Human alveolar deposition fraction,
assuming a monodispersed aerosol and a single mode
distribution, for a MMAD of 5.5 μm was estimated toilities. Electron microscopy of filters collected from personal breathing
ore agglomerated panel (B-D).
Erdely et al. Particle and Fibre Toxicology 2013, 10:53 Page 5 of 14
http://www.particleandfibretoxicology.com/content/10/1/53be 4% [33,34]. Therefore, alveolar deposition in the
worker was calculated as follows:
Human : Airborne Conc
 VE x exposure duration
 alveolar deposition efficiency
¼ human alveolar deposition
For 10:6 μg=m3 : 10:6 μg=m3
  20L=minð Þ
 10−3m3=L  8hr=dð Þ
 60min=hð Þ  4%
¼ 4:07 μg=d alveolar deposition
The extrapolation showed that a worker exposed to an
inhalable EC concentration of 10.6 μg/m3 for an 8 hour
day can roughly expect an approximate alveolar depisition
of 4.07 μg/d assuming a MMAD of 5.5 μm. This depos-
ition was then converted to mouse equivalence by alveolar
surface area [35]:
Human Deposition=Human Alveolar Surface Area




Mouse equivalent alveolar deposition ¼ x ¼ 2ng=d
Therefore, in a mouse this worker exposure is equivalent
to 2 ng/d.
Using previously determined alveolar depositions (de-
tailed in the Methods), mice were exposed to MWCNT by
inhalation for 4 weeks (19 d of inhalation over 26 d) to
deliver an alveolar lung burden of 1970 ng/d, 197 ng/d, or
19.7 ng/d (Table 2). The daily deposition in the low dose
group represents approximately 10 d of a human exposed
to an inhalable concentration of 10.6 μg/m3, the middle
dose 100 d, and the highest dose 1000 d. Therefore, our
cumulative 19 d deposition using a standard 5 day
workweek for 250 d/yr for an individual exposed to an
inhalable EC concentration of 10.6 μg/m3 was 190 d
(0.76 yr), 1900 d (7.6 yr), or 19,000 d (76 yr) for the low,
middle, and high dose respectively (Table 2).
Caveats of the above extrapolation were the MMAD of
5.5 μm and utilization of mass as the dose metric. As
shown in Figure 2, the potential exists for a range of dis-
persions in the facility which would affect the MMAD
and, therefore, the alveolar deposition. The inhalationTable 2 Predicted lung burden and relationship to human eq
Exposure Total lung
burden per day (ng)
Alveolar
burden per
5 mg/m3 for 5 h/d for 19 d 2340 1970
0.5 mg/m3 for 5 h/d for 19 d 234 197
0.5 mg/m3 for 0.5 h/d for 19 d* 23.4 19.7
*Mice were exposed to air for 4.5 h prior to 0.5 h of MWCNT to maintain consistencsystem developed at NIOSH for in vivo testing dispersed
the MWCNT used in this study to a MMAD of 1.5 μm
[27]. If a MMAD of 1.5 μm was observed in a MWCNT
facility, then the estimated alveolar deposition would in-
crease from 4% to 11% [33,34]. Extrapolating 11% alveolar
deposition, the inhalation design of this study would rep-
resent 0.27, 2.7, and 27 years of a human exposed to an
inhalable EC concentration of 10.6 μg/m3. Lastly, extrapo-
lation of effects in this study assumes complete exposure
and does not take into account respirator protection. The
correct and properly fitted respirator would protect
according to the assigned protection factor.
The exposure assessment data and extrapolations from
this study were done using mass-based analysis as op-
posed to fiber number (e.g. nanotubes/cm3). Currently,
NIOSH is attempting to develop methodologies utilizing
controlled inhalation exposures to MWCNT to accurately
assess the fiber number in the aerosol [27] and such fiber
count methodologies are being explored from the col-
lected human PBZ from this study. Even when counting
methodologies are utilized, it will be difficult to link dir-
ectly to end-point pathology as degree of dispersion can
affect pulmonary fibrosis and recent evidence suggests
the potential for larger agglomerates to dissociate into
smaller structures or singlets over time [30]. Difficulties
will also arise based on the type of CNT material being
produced and handling procedures which will alter the
agglomerate characteristics and potentially the pathology.
Given the current REL for CNT of 1 μg/m3 is a mass-
based measurement [28], extrapolations from this study
utilized mass.
Inhalation toxicology
In vivo inhalation parameters
Representative SEM images of aerosolized MWCNT
collected from the most populated stage of a Nano
MOUDI from the rodent inhalation study indicated a
well dispersed material (Figure 3). The mass median
aerodynamic diameter was 1.50 μm with a geometric
standard deviation of 1.67. The count mode aerodynamic
diameter was ~400 nm. In addition, there were no differ-
ences in inhalation parameters when comparing 5 mg/m3
to 0.5 mg/m3. The summary of inhalation parameters





Alveolar lung burden compared to
human exposed at 10 μg/m3 for 8 h
Daily (cumulative)
37.43 1000 days (76 years)
3.74 100 days (7.6 years)
0.37 10 days (0.76 years)
y of total exposure time.
Figure 3 Images of multi-walled carbon nanotubes (MWCNT) from the rodent inhalation study. Scanning electron microscopy images of
MWCNT collected on the most populated stage of a Nano MOUDI, showing a well-dispersed material. The images represent four different
magnifications indicated by the scale bars (20, 10, 5, and 1 um). The 5 μm scale bar had a pore size (dark circles) of 2.5 μm and the other three
figures had a pore size of 0.1 μm. The mass median aerodynamic diameter of the material was 1.5 μm. The count mode aerodynamic diameter
was ~400 nm.
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design (Table 3). Figure 4 shows a comparison of this
design to 7 other inhalation dose–response studies
utilizing MWCNT by cumulative concentration multi-
plied by time (C x T) [1-5,10,11]. The studies by Li
et al. and Porter et al. varied the days of exposure while
keeping the concentration constant [1,5]. The high
dose group was exposed at a daily rate consistent with
high dose exposures of previous studies with a cumula-
tive C x T expected to cause inflammation and histo-
logical changes (Figure 4). The middle dose provided a
cumulative deposition comparative to the lowest doses
used in the 13 week inhalation studies by Pauluhn andTable 3 Summary of inhalation exposure parameters
Daily exposure concentr
Experiment Mean concentration (mg/m3) RSD (%)
1 – High dose 4.67 7.8
2 – Middle dose 0.49 6.3
3 – Low dose 0.32 6.8
4 – High dose 4.68 9.4
5 – Middle dose 0.48 5.7
6 – Low dose 0.42 6.5
RSD Relative standard deviation.
*Exposure for 19 day.Ma-Hock et al. [3,4]. The low dose was the same as a
recently published study with expectations of a no
effect level [2].
Pulmonary response to MWCNT inhalation exposure
The high dose of MWCNT inhalation exposure, as
expected, resulted in marked cytoxicity, as measured by
bronchoalveolar lavage (BAL) lactate dehydrogenase
(LDH) activity, that was maintained 84 d post-exposure
(Figure 5). The middle dose resulted in transient cyto-
toxicity that returned to baseline by 3 d. There was no
cytotoxicity measured at the lowest lung burden. Loss of
epithelial barrier integrity, measured as BAL albumination and duration Exposure dose*







Figure 4 Comparison of effects among studies of inhalation
exposure to multi-walled carbon nanotubes (MWCNT).
Cumulative MWCNT exposures (concentration (C) x time (T) – mg/m3
multiplied by total hours of exposure) were plotted on a
logarithmic scale from studies that exposed rodents by inhalation
to various doses of MWCNT (black circles). Measured toxicologic
endpoints were identified for each cumulative exposure. Symbols
represent histopathologic alterations (*), increased bronchoalveolar
lavage (BAL) polymorphonuclear cell (PMN) influx or enzyme
activity ($), increased BAL total protein or albumin (^), increased
tissue or BAL cytokines (@), and alterations in mRNA expression (&).
The lack of a symbol means either the endpoint was not measured
or there was no effect due to treatment. Symbols in parantheses
indicate either a transient effect, the effect was scored as minimal,
or the response was not consistently measured at all post-exposure
time points for that given cumulative C x T. Each of the 5
toxicologic endpoints were highlighted by an arbitrary cutoff
(dashed lines) to illustrate the threshold cumulative C x T to result
in significant pulmonary responses in general agreement across
various study designs. The numbers representing the dashed lines
are as follows: 5 – histological alterations, 4 – increased BAL PMN
influx or enzyme activity, 3 – increased BAL total protein or
albumin, 2 – increased tissue or BAL cytokines, and 1 – alterations
in mRNA expression. The years indicated on the left side of the
graph are the extrapolations of the mouse lung burden from this
study to represent years of worker exposure to an inhalable
elemental carbon concentration of 10.6 μg/m3 assuming 25%
respirability which predicts a MMAD of 5.5 μm.
Figure 5 Effect of multi-walled carbon nanotube (MWCNT)
inhalation on pulmonary cytotoxicity at different time points
after exposure. Lactate dehydrogenase (LDH) activity (U/L), an
indication of cytotoxicity, was measured from the first fraction of
collected bronchoalveolar lavage fluid. Data are expressed as percent
(%) change from respective sham (dashed line – 100%). N.D. – not
determined. #p<0.05 vs. other MWCNT depositions for a given time
point only.
Figure 6 Effect of multi-walled carbon nanotube (MWCNT)
inhalation on pulmonary permeability at different time points
after exposure. Albumin (mg/dL), an indication of a loss of epithelial
barrier integrity, was measured from the first fraction of collected
bronchoalveolar lavage fluid. Data are expressed as percent (%) change
from respective sham (dashed line – 100%). N.D. – not determined.
*p<0.05 vs. respective sham; #p<0.05 vs. other MWCNT depositions for
a given time point only.
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high dose of MWCNT (Figure 6). The middle dose also
showed increased levels of albumin that persisted through
84 d post-exposure. There was no effect at the low dose.
The middle inhalation dose did not result in any sig-
nificant polymorphonuclear (PMN) cell influx (Figure 7).
These data suggest that exposures to purified MWCNT
at dose levels relevant to occupational exposures do not
elicit a PMN influx. From an extrapolated dosimetry ar-
gument, PMN accumulation is not likely a major factor
in the occupational setting without considerable accu-
mulation or inflammatory contamination (e.g. catalytic
metals, endotoxin). The high dose showed a significant
PMN influx of 7.7% at 0 d (Figure 7) with significant
levels maintained through 84 d (data not shown). The %of PMN is in sharp contrast to our previous work show-
ing that 4 h after a 40 μg bolus dose of MWCNT the dif-
ferential % of PMN was 55% [8]. It is unclear the impact
of the lack of a PMN response at human relevant expo-
sures. Previous studies have shown that peroxidases pro-
duced by PMN could facilitate the degradation of CNT
[36,37]. The loss of that potential degradation mechanism
and reduced overall inflammation may affect the life cycle
of MWCNT in the lung. Ongoing quantitative studies are
assessing the linearity of pulmonary distribution and fate
Figure 7 Effect of multi-walled carbon nanotube (MWCNT)
inhalation on pulmonary inflammatory cell influx at 0 d
post-exposure. Polymorphonuclear cells, an indication of pulmonary
inflammation, were measured from reconstituted pellets of the
bronchoalveolar cellular fraction. H = high dose; M = middle dose; L =
low dose. Data are expressed as percent (%) PMN from a total of 300
cells counted slides from cytospins. *p<0.05 vs. respective sham.
Figure 8 Effect of multi-walled carbon nanotube (MWCNT)
inhalation on pulmonary inflammatory gene expression at
different time points after exposure. Interleukin 6 (Il6),
chemokine (C-C motif) ligand 2 (Ccl2; also referred to as
monocyte chemotactic protein-1), and chemokine (C-X-C motif)
ligand 2 (Cxcl2; also referred to as macrophage inflammatory
protein 2-alpha) were measured. Data are expressed as percent
(%) change from respective sham (dashed line – 100%). Data
presented as high dose (gray bars), medium dose (pattern), and
low dose (black bars). *p<0.05 vs. respective sham; #p<0.05 vs.
other MWCNT depositions for a given time point only.
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sponse study.
Additional measures of inflammation, including tissue
mRNA expression changes and BAL mediator levels,
were measured. As expected, levels of mRNA expres-
sion in the lung of several classic inflammatory media-
tors, including interleukin 6 (Il6), chemokine (C-C
motif ) ligand 2 (Ccl2; also referred to as monocyte
chemotactic protein-1), and chemokine (C-X-C motif )
ligand 2 (Cxcl2; also referred to as macrophage inflam-
matory protein 2-alpha), were increased through 84 d
following the high dose exposure (Figure 8). There were
also effects at the middle dose for all 3 genes and at the
low dose for Ccl2 and Cxcl2 (Figure 8). BAL fluid pro-
tein levels of Il-6 and Ccl2 were increased at the high
dose but did not reach the level of detection using
multiplex technology for the middle and low doses, so it
is unclear beyond the high dose whether increased
transcription contributes to a corresponding increase in
protein levels (data not shown). Conversely, BAL pro-
tein levels for Cxcl2, chemokine (C-C motif ) ligand 7
(Ccl7; also known as monocyte-specific chemokine 3),
and chemokine (C-C motif ) ligand 9 (Ccl9; also known
as macrophage inflammatory protein-1 gamma) wereincreased (Figure 9), indicating the presence of inflam-
matory mediators at least 28 d post-exposure to the
middle dose.
The BAL inflammatory findings detailed in this study
qualitatively agree with those of other MWCNT inhal-
ation studies (Figure 4). Porter et al. reported cytotoxicity
and increased PMN at the lowest cumulative C x T expos-
ure dose of 100 mg/m3 x h. [5]. Studies using lower cumu-
lative exposures showed no cytotoxicity or PMN influx
[4,10]. In this study, there was a transient increase in cyto-
toxicity at 0 d in the middle dose. This indicates that 19 d
inhalation of 0.5 mg/m3 for 5 h/d is cytotoxic but the
deposition level of 197 ng/d did not sustain the response
for the particular MWCNT studied. Changes in BAL total
protein or albumin appears to have a lower threshold. The
middle dose in this study as well as the low dose in the
Pauluhn study indicated increased BAL albumin and total
protein, respectively [4]. Increased BAL albumin levels
without cytotoxcity have been observed following other
particulate exposures [38]. As should be expected, not all
studies are in perfect agreement with the arbitrary cutoffs
in Figure 4. In particular, a recent study by Ma-Hock et al.
showed significant cytotoxicity at lower C x T than the
transient response of the middle dose from this study
without increased total protein in the BAL [2]. Increased
inflammatory proteins were measured in the BAL at the
middle dose in the panel analyzed; this is in agreement
with previous studies [5,11] as well as the middle dose by
Figure 10 Effect of multi-walled carbon nanotube (MWCNT)
inhalation on pulmonary chemokine (C-C motif) ligand 22
(Ccl22) at different time points after exposure. Pulmonary tissue
gene expression (upper panel) and protein levels from the first
fraction of collected bronchoalveolar lavage fluid were measured.
Data are expressed as percent (%) change from respective sham
(dashed line – 100%). Data presented as high dose (gray bars),
medium dose (pattern), and low dose (black bars). N.D. – not
determined. *p<0.05 vs. respective sham; #p<0.05 vs. other MWCNT
depositions for a given time point only.
Figure 9 Effect of multi-walled carbon nanotube (MWCNT)
inhalation on pulmonary inflammatory protein levels at
different time points after exposure. Chemokine (C-X-C motif)
ligand 2 (Cxcl2), chemokine (C-C motif) ligand 7 (Ccl7), and
chemokine (C-C motif) ligand 9 (Ccl9) were measured from the first
fraction of collected bronchoalveolar lavage fluid. Data are expressed
as percent (%) change from respective sham (dashed line – 100%).
Measurements were made from all doses at 0 d and the high and
middle dose at 28 d since no effect was observed in the low dose
at 0 d. Data presented as high dose (gray bars), medium dose
(pattern), and low dose (black bars). *p<0.05 vs. respective sham; #p<0.05
vs. other MWCNT depositions for a given time point only.
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the threshold for marked cytotoxicity or PMN influx.
Lastly, increased transcription of inflammatory markers
was evident at the lowest cumulative C x T (Figure 4). Al-
though increased protein levels were not evident, these
data show a low level of underlying inflammatory signaling
at lung burdens which do not cause any measurable tox-
icity. The increased mRNA expression may be in response
to the process of pulmonary handling of the daily nano-
gram levels of deposited MWCNT. The genes measured
in Figure 8 are either produced by or enhance the accu-
mulation of macrophages. The MWCNT used in this
study were primarily found in alveolar macrophages fol-
lowing exposure supporting macrophage-related signaling
[39]. Ongoing studies are using global mRNA expression
profiling by microarray paired with subsequent pathway
analysis to compare and contrast response mechanisms
associated with a high dose exposure and a lung burden
more relevant to the workplace. Given that transcriptional
changes were evident at a 10 times lower deposition than
necessary to induce more traditional markers of pulmon-
ary toxicity, the approach seems logical. Many of the
human analogs for these gene expression products are be-
ing analyzed in a cross-sectional study of workers exposed
to CNT or CNF [26].
One mediator of interest was chemokine (C-C motif) lig-
and 22, also referred to as macrophage-derived chemokine.Studies involving first responders to 9/11 have shown that
early increased serum CCL22/MDC correlated to declining
pulmonary function in subsequent years [40]. In vitro
studies showed that alveolar macrophages were the pre-
dominant producers of CCL22/MDC when compared
to primary epithelial cells [41]. In a previous exposure
study, pulmonary expression of Ccl22, with associated
Ccl22 protein levels in the serum, were increased after a
bolus dose of 40 μg MWCNT [8]. A more recent study
confirmed those early findings of increased circulating
Ccl22 [14]. Here, pulmonary expression levels were
increased even at the lowest exposure dose (Figure 10),
indicating the particular sensitivity of this mediator to
MWCNT exposure in a mouse model. In addition to
mRNA expression, protein levels in the BAL fluid were
increased at the high and middle dose through 28 d
post-exposure. Protein levels were not significantly in-
creased at the lowest dose at 0 d. As future studies begin
to uncover the molecular mechanisms associated with
the pathology of MWCNT, especially at workplace rele-
vant exposures, certain mediators, such as CCL22/MDC,
may be more sensitive in determining exposure.
Pulmonary pathology of MWCNT
Mice tissues were harvested at 84 d post-exposure for pul-
monary pathology. Only at the highest dose were changes
indicated and included increased peribronchiolar inflam-
mation and bronchiolar epithelial hyperplasia around the
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imal (1 on a 1–5 scale) in the MWCNT-exposed mice
(Figure 11). Peribronchiolar inflammation incidence was
5/5 in MWCNT-exposed mice and 1/5 in air exposed
shams and bronchiolar epithelial hyperplasia incidence
was 5/5 in MWCNT-exposed mice and 0/5 in air exposed
shams. As opposed to aspiration studies, there were no
granulomas scored in this study, a finding consistent with
inhalation using this particular MWCNT [5]. Overall
fibrosis, determined solely from trichrome staining, was
scored as negative. The findings are not unexpected as
previous studies indicate the lack of pronounced diffuse
pulmonary fibrosis at similar cumulative exposures [3].
Total collagen was not assessed in these studies and de-
tailed morphometric analysis of the interstitium is under-
way. A previous study of 5 mg/m3 for 12 d, 7 d less
exposure than the high dose from this study, showed a
53% increase in alveolar thickening by morphometric ana-
lysis [30]. While it is likely that detailed morphometric
analysis would show evidence of interstitial fibrosis, the
extrapolations to human relevancy suggest decades of
continued exposure at an inhalable EC concentration of
10.6 μg/m3 may be necessary for substantial fibrosis to
present. While risk was not defined in this study, the
findings qualitatively support the recommended exposureFigure 11 Effect of multi-walled carbon nanotube (MWCNT) inhalatio
exposed to the high dose (5 mg/m3 for 5 h/d for 19 d) and examined 84 d
that have accumulated in connective tissue immediately below the thicken
rest of the lung, general fibrosis, as identified by Trichrome staining, was sc
effects were scored for the middle and low dose exposures. The arrows in
respective right panel.limit predicting 0.5-16% risk of developing early-stage lung
effects over a working lifetime (45 years) exposed to an 8
h time-weighted average of respirable EC concentrations
of 1 μg/m3 [28].
One effect that was not considered or measured in this
study, or those evaluated in Figure 4, was the potential for
carcinogenicity. Recent work by Sargent et al. showed that
inhalation of MWCNT promoted mouse lung tumor for-
mation following initiation by 3-methylcholanthrene [7].
The C x T for that study was 375 mg/m3 x h (5 mg/m3 x
15 d x 5 h/d) putting the cumulative exposure in the top
tier of studies in Figure 4. While the data did not indicate
initiation by MWCNT, they also did not show a no effect
level for promotion. This was similar to in vitro studies
that showed chromosomal effects were still measured at
the lowest administered dose of 0.024 μg/cm2 [42]. There-
fore, a cutoff for extrapolated lung burden that would not
result in tumor promotion cannot be currently deter-
mined, further indicating caution when handling CNT.
Limitations
Several limitations were inherent to this study. One limita-
tion was mass-based EC concentration cannot distinguish
between other carbon species (e.g. diesel exhaust, burning
of biomass, or other forms of nanomaterials such asn on pulmonary pathology. Images are representative from mice
post-exposure. In the upper panels, MWCNT are within macrophages
ed epithelium of the terminal bronchiole (TB). In comparison to the
ored as negative in MWCNT-treated mice (lower panels). No significant
the left panels indicate the area of higher magnification shown in the
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to MWCNT. However, all efforts were attempted to
minimize this by subtracting anthropogenic background
concentrations of elemental carbon for each sample. For
the human dosimetry calculation, we had to make several
assumptions including using a fixed respirability to
inhalability ratio to estimate the MMAD that was not
specifically measured in the field. We used all of the
the empirical data available to estimate an average
deposition although it should be understood that varia-
tions in those parameters will affect alveolar depos-
ition. Another limitation is the relatability of the
animal exposure to the MWCNT found in workplace
facilities. The MWCNT used in the animal inhalation
study is a material that disperses very well as compared
to many of the images observed from the PBZ samples.
The inhalation material was also able to penetrate into
the pleural space which is less likely for more agglom-
erated or thinner more flexible CNT [43]. Therefore,
we believe that the toxicity for this particular exposure
resides more in the worst case scenario category. To
provide further insight, ongoing studies are evaluating
toxicological endpoints of materials utilized by U.S.
facilities.
Conclusions
The cutoffs in Figure 4 were made in an arbitrary fashion
from consensus findings across all studies. Discrepancies
include the beginnings of histological aberrations at a
lower dose [3], no PMN influx at any dose [10], and the
transient LDH response soon after cessation of exposure
at the middle dose of this study. In general, the recent
findings from Ma-Hock et al. have increased pulmonary
toxicity at lower cumulative C x T compared to other
MWCNT inhalation studies depicted in Figure 4 [2]. The
differences between studies can be the result of different
MWCNT structures produced by different inhalation
system generations, differences in the types of MWCNT
tested, timing of measurements, and the age, strain, and
species used in each study. Irrespective, Figure 4 shows a
relatively uniform prediction of effects for traditional mea-
sures of pulmonary toxicity when normalized to cumula-
tive C x T with the assumption that a range exists for each
specific cutoff depending on the type of MWCNT and in-
halation exposure design. Recent studies have shown that
specific functionalization of CNT can alter the toxicity
[44-46]; it would be interesting to see how those materials
would differ under similar inhalation exposure designs as
previous studies.
The primary goal of this study was to provide context to
relate exposure assessment studies in facilities manufactur-
ing and handling MWCNT to dosimetry for in vivo rodent
exposures. Exposure assessment data indicated an average
inhalable EC concentration of 10.6 μg/m3 from PBZmeasurements. Assuming a 25% inhalable to respirable ra-
tio, the approximate respirable concentration is 2.65 μg/
m3. It is clear from toxicological evaluations that MWCNT
have a relatively high hazard when compared to other ma-
terials. These hazards may include fibrosis, promotion of
lung tumors, cardiovascular dysfunction, and pulmonary
and systemic inflammation. The present findings show
that limiting cumulative exposures is imperative to redu-
cing adverse effects.Methods
Exposure assessment
A literature search was performed for exposure assess-
ment studies at facilities handling MWCNT, SWCNT, or
CNF in which personal breathing zone mass-based sam-
ples were collected. A total of 7 studies, over the past 10
yr, met the above criteria and are listed in Table 1. These
studies represent a wide range of mass-based analysis
methods, industries, and exposure scenarios all producing
CNT/CNF or using the material downstream as a second-
ary manufacturer.
Exposure assessments were conducted at 8 different
facilities producing or using MWCNT. Five of these fa-
cilities were previously reported [23] and an additional
3 MWCNT facilities were added to create an inhalable
EC average from 8 facilities which were adapted to gen-
erate Figure 1. A detailed analysis of the findings from
all facilities will be published separately (Dahm et al.
[16], in preparation).
In brief, personal breathing zone, mass-based samples
were collected to estimate the inhalable size fraction
for EC. These samples were collected on open-faced,
25-mm-diameter quartz fiber filters (SKC Inc., Eighty
Four, PA, USA) using Leland Legacy pumps (SKC Inc.)
operating at 6–7 l min-1. The samples were subse-
quently analyzed according to NMAM Method 5040
[22] which is currently recommended by NIOSH to as-
sess exposures to CNTs/CNFs [28]. Background sam-
ples for EC were collected in the same manner due to
the potential interference from anthropogenic sources
of EC. The background samples were collected as in-
door or outdoor area samples based on the characteris-
tics of each facility.
Concurrent, side-by-side personal breathing zone
samples were also collected for transmission electron
microscopy (TEM) to confirm the presence of MWCNT.
Samples were collected on 25-mm mixed cellulose ester
filters (0.8-lm pore size; SKC Inc.) using Leland Legacy
pumps (SKC Inc.) operating at 5 l min-1. The TEM sam-
ples were then analyzed on a JEOL2100F TEM (JEOL
USA, Inc., Peabody, MA, USA) using a modified NMAM
7402, asbestos by TEM [47]. Additional details on the
sampling methodologies can be found in Dahm et al. [23].
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Specific pathogen-free, male C57BL/6J mice from Jackson
Laboratory (Bar Harbor, ME) were used in this study. All
mice housed in the AAALAC-approved NIOSH Animal
Facility were provided food and tap water ad libitum in
ventilated cages in a controlled humidity and temperature
environment with a 12 hr light/dark cycle. Animal care
and use procedures were conducted in accordance with
the “PHS Policy on Humane Care and Use of Laboratory
Animals” and the “Guide for the Care and Use of
Laboratory Animals” (NIH publication 86–23, 1996).
These procedures were approved by the National Insti-
tute for Occupational Safety and Health Institutional
Animal Care and Use Committee.
C57BL/6J mice, eight weeks of age, were exposed by
inhalation to MWCNT (produced by Hodogaya, Japan)
at various parameters to achieve two orders of magni-
tude range of lung burdens as shown in Table 2. Animals
were exposed using a computer controlled whole body
inhalation exposure system designed and constructed at
NIOSH [48]. In brief, the inhalation exposure system
combines air flow controllers, aerosol particle monitors,
data acquisition devices, and custom software with auto-
matic feedback control to achieve constant and repeat-
able exposure chamber temperature, relative humidity,
pressure, aerosol concentration, and particle size distri-
butions. The MWCNT used in this study have been
extensively characterized previously [5,49]. The average
diameter was 49 nm with a length of 3.86 μm (GSD
1.94). Purity was >99% carbon. Mice were exposed for
19 d over a total of 26 d (mice were not exposed for the
three weekends and the second Monday of each four
week exposure). The doses chosen were 5 mg/m3 for 5 h/d,
0.5 mg/m3 for 5 h/d, and 0.5 mg/m3 for 0.5 h/d. The low-
est dose method was chosen because consistency was
questioned in tests of exposure levels at 0.05 mg/m3. In
this group, mice were exposed to air for 4.5 h then
MWCNT for 0.5 h to maintain the same timeframe as the
two other groups. Mice were euthanized at 0 d (immedi-
ately following the last exposure), 3 d, 28 d, and 84 d. The
left lung lobe was ligated and frozen in liquid nitrogen and
the right lung lobes were lavaged. Two separate groups
were exposed for each dose for a total of n=12 air and
n=12 MWCNT at each time point unless otherwise indi-
cated. Mice in set one were used for histopathology (n=6
air; n=6 MWCNT) at 84 d post-exposure and mice in set
two were used to include 3 d post-exposure (n=6 air; n=6
MWCNT).
Lung burden of MWCNT
Previous studies have determined that male C57BL/6J
mice exposed to 5 mg/m3 for 12 d have a total lung
burden of 28.1 μg, or 2.34 μg/d [30]. In that same
study, alveolar deposition was calculated at 84% of thetotal lung burden (or 1.97 μg/d). Assuming linearity,
these values were extrapolated to achieve the lung
burdens shown in Table 2. While these values are
estimates because of the assumption of linearity, the
values were generated from previously quantitated
lung burdens in aged matched male mice of the same
strain, C57Bl6/J [5,30].
Bronchoalveolar lavage (BAL)
BAL collected from right lobes was assessed for lactate
dehydrogenase activity, albumin concentration, and in-
flammatory protein concentrations. Differentials from
the cellular fraction were made from counts of 300 cells
per slide stained with Wright-Giemsa stain.
Pulmonary gene expression
RNA was isolated from frozen lung using the RNeasy Mini
Kit (Qiagen, Valencia, CA, USA). Evaluation of gene ex-
pression was determined by standard 96-well technology
using the StepOne™ (Applied Biosystems, Carlsbad, CA,
USA) with pre-designed Assays-on-Demand™ TaqMan®
probes and primers including Il6 (Mn00446190_m1), Ccl2
(Mn00441242_m1), Cxcl2 (Mn00436450_m1), and Ccl22
(Mn00436439_m1) (Applied Biosystems). Using 96 well
plates, one μg of total RNA was reverse transcribed
using random hexamers (Applied Biosystems) and
Superscript III (Invitrogen, Carlsbad, CA). Nine μl of
cDNA (1/10) was then used for gene expression determin-
ation. Hypoxanthine-guanine phosphoribosyltransferase
was used as an internal reference. Relative gene expression
was calculated using the comparative threshold method
(2-ΔΔCt) with vehicle-treated mice serving as the reference
group [50].
BAL protein analysis
Collected acellular first fraction BAL was sent to Myriad /
RBM (Austin, TX) for protein profiling by multiplex
immunoassay RodentMAP v3.0. Only select proteins
were used for illustration in the manuscript and the
complete analysis will be published in a subsequent
manuscript.
Histopathology
Right lung sections were cut, stained, and sent for histo-
pathology assessment by Charles River Research Animal
Diagnostic Services. Histopathology that was assessed
included peribronchiolar inflammation, bronchiolar epi-
thelial hyperplasia, and fibrosis. Sections were scored on
a 1–5 scale where 1=minimal and 5=severe.
Statistics
Statistical analysis of all outcome variables was performed
using SAS version 9.3 for Windows. The exposure assess-
ment PBZ EC concentrations were calculated, specific to
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from the PBZ data. This was done to separate any
anthropogenic EC sources from potential CNT/CNF EC
exposures. Any samples that were below the limit of de-
tection (LOD) for method 5040 were calculated by taking
the LOD of the method and dividing it by two and then
calculating the air concentration using the volume of that
specific sample. These data were used to calculate the
arithmetic means and SD. In order to calculate the geo-
metric means and GSDs, the data were log transformed.
The normality of the log-transformed data were assessed
using the Shapiro-Wilk test.
Data from rodent studies were log transformed prior to
analysis to meet the assumptions of the statistical tests.
roc Mix was used to run a three-way factorial analysis of
variance. Significant three-way interactions were examined
by utilizing two-way ANOVA’s stratified by time. Pairwise
comparisons were performed using Fishers Least Signifi-
cant Difference test. Differences between experimental
groups were considered significant with p-values less than
0.05.
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